leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12345678910111213...235236»
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Journal, PD(L)-1 Biomarker, IO biomarker:  Update for: New developments in systemic therapy for advanced biliary tract cancer. (Pubmed Central) -  Feb 4, 2025   
    As first-line systemic therapy, the addition of an immune checkpoint inhibitor, such as durvalumab or pembrolizumab, to gemcitabine plus cisplatin has been shown to prolong overall survival compared with gemcitabine plus cisplatin...Regarding second-line treatment after a gemcitabine-based regimen, fluorouracil and folinic acid plus oxaliplatin have been the standard regimen. Additionally, FGFR2 fusion gene/rearrangement, mutations of IDH1/2, KRAS, and BRAF, and overexpression of HER2 are promising therapeutic targets for which the effectiveness of each targeted therapy has been reported, at this time, as a second-line or later treatment.
  • ||||||||||  Ampligen (rintatolimod) / AIM ImmunoTech
    Trial completion date, Trial primary completion date:  Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov) -  Feb 4, 2025   
    P2,  N=90, Recruiting, 
    To address this unmet need, global metabolomic profiling was performed on tumor tissue and paired serum samples from patients with treatment-na Trial completion date: Jul 2028 --> Oct 2028 | Trial primary completion date: Jun 2028 --> Sep 2028
  • ||||||||||  tilatamig samrotecan (AZD9592) / AstraZeneca
    Enrollment change, Monotherapy:  EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) -  Feb 4, 2025   
    P1,  N=228, Recruiting, 
    Not yet recruiting --> Recruiting N=162 --> 228
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Risk Prediction of Myelosuppression Following First-line Chemotherapy in Colorectal Cancer. (Pubmed Central) -  Feb 3, 2025   
    This retrospective study analyzed 855 CRC patients from Guang'anmen Hospital who received first-line chemotherapy (CapeOx, FOLFOX, FOLFIRI) between April 2020 and July 2024...Limitations include potential selection bias and the need for external validation in diverse populations. Future studies should further refine and validate this predictive model.
  • ||||||||||  Clinical data, Review, Journal, HEOR, Real-world evidence, Real-world, Metastases:  Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review. (Pubmed Central) -  Feb 3, 2025   
    This systematic review summarizes real-world clinical outcomes and economic burden of first-line FOLFIRINOX (FFX)/modified FFX (mFFX) and nab-paclitaxel plus gemcitabine (GnP) in metastatic pancreatic ductal adenocarcinoma in the US...Outpatient, supportive care, and granulocyte colony-stimulating factor costs were higher for the FFX generic regimen, and chemotherapy costs were higher for the GnP branded regimen. Real-world OS in FFX- and GnP-treated populations was shorter than that in clinical trials, and total costs of FFX and GnP were similar, but with differences in cost components.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment closed:  Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer (clinicaltrials.gov) -  Feb 3, 2025   
    P2,  N=155, Active, not recruiting, 
    Real-world OS in FFX- and GnP-treated populations was shorter than that in clinical trials, and total costs of FFX and GnP were similar, but with differences in cost components. Recruiting --> Active, not recruiting
  • ||||||||||  P3 data, Journal:  MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. (Pubmed Central) -  Feb 1, 2025   
    P3
    The MOUNTAINEER-03 phase III trial is designed to investigate the efficacy and safety of first-line tucatinib in combination with trastuzumab and modified FOLFOX6 (mFOLFOX6) versus standard of care (mFOLFOX6 plus bevacizumab or cetuximab) in patients with untreated HER2+, RAS WT locally advanced unresectable or mCRC...Key secondary endpoints are overall survival and confirmed objective response rate (according to RECIST v1.1 per BICR). Safety assessments will include surveillance and recording of adverse events, physical examination findings, vital signs, cardiac assessments, Eastern Cooperative Oncology Group performance status, concomitant medications, and laboratory tests.Clinical trial registration: NCT05253651 (ClinicalTrials.gov).
  • ||||||||||  methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Prevention and Treatment of Acute Kidney Injury Associated with High Dose Methotrexate. (Pubmed Central) -  Jan 31, 2025   
    Glucarpidase (carboxypeptidase-G2), a recombinant bacterial enzyme that hydrolyzes MTX into two non-cytotoxic metabolites, should be considered for patients with MTX overexposure to prevent and lessen AKI and other potential toxicities. This article provides a comprehensive review of MTX metabolism, mechanisms and prevention of MTX-AKI, and its management.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Stage-specific characterization of "early-onset colorectal cancer": Localized and synchronous metastatic disease. (Pubmed Central) -  Jan 31, 2025   
    This article provides a comprehensive review of MTX metabolism, mechanisms and prevention of MTX-AKI, and its management. Among localized patients, female gender (58.1% vs. 40%, p?=?.008), perineural invasion (41.9% vs. 24.9%, p?=?.005), folinic acid, 5-fluorouracil, and oxaliplatin chemotherapy (45.2% vs. 25.2%, p?=?.003), and perioperative chemotherapy cycles (9.21 [
  • ||||||||||  Straight from the Heart: Late Onset Cardiac Toxoplasmosis in a Heart Transplant Recipient (Poster Hall) -  Jan 19, 2025 - Abstract #ISHLT2025ISHLT_439;    
    Tacrolimus, mycophenolate mofetil, and prednisone were used for maintenance immunosuppression...Patient was started on acyclovir, vancomycin, ceftriaxone, and ampicillin for broad-spectrum coverage...First line treatment included: pyrimethamine, sulfadiazine and leucovorin...The use of microbial cell-free DNA testing assisted in rapid diagnosis in this patient with non-specific symptoms. Further research is needed to determine if extended prophylaxis in high-risk T. gondii mismatches can help prevent late-onset infections.
  • ||||||||||  Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
    Clinical, Retrospective data, Journal:  First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial. (Pubmed Central) -  Jan 17, 2025   
    P3
    In patients with colorectal cancer and unresectable liver-only metastases (CRLM), treatment with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus irinotecan (FOLFOXIRI) and bevacizumab vs FOLFOX/folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus bevacizumab increased progression-free survival, response, and R0/R1 resection/ablation rates, as well as toxic effects in RAS/BRAFV600E-variant and/or right-sided tumors...To present long-term outcomes of treatment with FOLFOXIRI plus bevacizumab vs FOLFOX/FOLFIRI plus bevacizumab and FOLFOX/FOLFIRI plus panitumumab vs FOLFOX/FOLFIRI + bevacizumab...ACT might be considered for these patients. ClinicalTrials.gov NCT02162563.
  • ||||||||||  Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker:  C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. (Pubmed Central) -  Jan 15, 2025   
    PDAC patients with long survival have higher hENT1 expression levels. Furthermore, CRP expression is a biomarker of poor prognosis following perioperative chemotherapy and resection in PDAC patients and thus may be useful for identifying patients who could benefit from more aggressive adjuvant strategies.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Hypoxia-Associated GPNMB+ Macrophages Promote Malignant Progression of Colorectal Cancer and Its Related (Pubmed Central) -  Jan 13, 2025   
    Additionally, HMRS was identified as an independent prognostic factor in other digestive tract tumors (hepatocellular carcinoma, pancreatic cancer, esophageal cancer, and gastric cancer), indicating potential extrapolation to other tumor types. In conclusion, GPNMB+ Macr promotes the malignant progression of CRC, and HMRS serves as a powerful predictive tool for prognosis, chemotherapy, and immunotherapy in CRC patients, aiding in improving the quality of survival.
  • ||||||||||  Vectibix (panitumumab) / Amgen
    P2 data, Journal:  Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in (Pubmed Central) -  Jan 13, 2025   
    P2
    In conclusion, GPNMB+ Macr promotes the malignant progression of CRC, and HMRS serves as a powerful predictive tool for prognosis, chemotherapy, and immunotherapy in CRC patients, aiding in improving the quality of survival. In this final phase 2 trial analysis, adult mCRC patients responding to six cycles of FU/FA, oxaliplatin and panitumumab were randomized (1:1, open-label) to maintenance of either FU/FA
  • ||||||||||  paclitaxel / Generic mfg.
    Trial completion date, Trial primary completion date:  STOPGAP: Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis (clinicaltrials.gov) -  Jan 13, 2025   
    P2,  N=40, Recruiting, 
    In this final phase 2 trial analysis, adult mCRC patients responding to six cycles of FU/FA, oxaliplatin and panitumumab were randomized (1:1, open-label) to maintenance of either FU/FA Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Advanced-stage duodenal cancer in pregnancy. (Pubmed Central) -  Jan 12, 2025   
    To the author's knowledge, there are no studies that describe the management of advanced duodenal cancer during pregnancy and this case highlights the importance of creating a multidisciplinary team and incorporating shared decision-making when discussing diagnostic workup and treatment options, including the use of cytotoxic therapy during pregnancy, with patients. This study will also discuss maternal and fetal outcomes after the administration of FOLFOX (leucovorin, fluorouracil and oxaliplatin) chemotherapy during the second trimester.
  • ||||||||||  Journal:  Metastatic pancreatic cancer now in remission: a case report and literature review. (Pubmed Central) -  Jan 12, 2025   
    Despite a stage IV diagnosis, the primary tumor was resected in order to mitigate the risk for mutation and progression. Although rare, greater hope for patients with PDAC of the tail with favorable tumor biology responsive to FOLFIRINOX may contribute to increased surgical resection rates and improve survival rates.